Connected drug delivery devices market to grow to $4bn by 2028
A new report reveals the COVID-19 pandemic, prevalence of chronic disease and increasing patient engagement will all drive adoption of connected drug delivery devices.
List view / Grid view
A new report reveals the COVID-19 pandemic, prevalence of chronic disease and increasing patient engagement will all drive adoption of connected drug delivery devices.
The EMA's human medicines committee has adopted a positive opinion for eight medicines, recommending their marketing authorisation.